Business as usual as Germany moves on with fast-tracking plan
This article was originally published in Clinica
Election or no election, there have been few concerns in Germany about the Erprobungsregelung – the mechanism that will allow the speeding into usage of promising yet insufficiently-tested products –coming to an untimely end under a new governing administration.
You may also be interested in...
Germany’s system for fast-tracking selected, insufficiently proven ambulatory medtech products into commercial use seems to be falling short of its potential. This has set alarm bells ringing in an industry that is already concerned about its inpatient pass-through scheme (NUBs).
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”